PMC utilizes quantitative real-time PCR (qPCR) technology for highly sensitive pathogen detection, quantification, and optional antibiotic resistance gene identification. This advanced molecular approach enables the identification of organisms that are slow-growing, fastidious, or difficult to culture using conventional diagnostic methods.The PMC STI Panel is specifically designed for use in both male and female patients and targets 14 clinically relevant bacterial and viral pathogens associated with sexually transmitted infections. This focused panel supports accurate diagnosis of both symptomatic and asymptomatic infections, including single and polymicrobial cases, that may otherwise go undetected. The PMC STI Panel provides clinicians with actionable diagnostic insights, enabling timely, precise, and cost-effective management of sexually transmitted infections.